Evidence Based Safety of Clinical Use of Dasiglucagon – A Comprehensive Review

Abstract

Severe hypoglycaemia is a key obstacle to optimal glycaemic control in type 1 diabetes, requiring rapid and consistent rescue treatments. Dasiglucagon, a ready‑to‑use stable glucagon analogue approved in 2021, offers a real-world substitute to old reconstituted glucagon. This review summarizes proof from clinical trials and real‑world studies assessing its safety. Dasiglucagon steadily restored plasma glucose within minutes, with nausea and vomiting being the utmost common side effects, similar to standard glucagon. Injection‑site reactions and immunogenicity were negligible, and the drug confirmed usefulness in special patients such as post‑bariatric surgery hypoglycaemia and congenital hyperinsulinism. Generally, dasiglucagon shows a promising safety profile and delivers an effective, fast, and user‑friendly option for treating severe and non‑severe hypoglycaemia.